Postoperative Assessment of Platelet-Rich Plasma and Platelet-Rich Fibrin in Temporomandibular Joint Surgery

January 21, 2026 updated by: Jingping Wang, MD, Ph.D.

Postoperative Assessment in TMJ Surgery: A Comparison of the Efficacy of Intraoperative Platelet-Rich Plasma and Platelet-Rich Fibrin Injections

The goal of this observational study is to evaluate postoperative outcomes following temporomandibular joint (TMJ) surgery and to compare the effectiveness of intraoperative platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) injections in patients with temporomandibular joint disorders.

The study includes adult patients who underwent TMJ surgery and received either PRP or PRF intraoperatively. The main questions this study aims to answer are:

Whether intraoperative PRP or PRF injection is associated with differences in postoperative pain intensity and recovery.

Whether PRP and PRF differ in their effects on postoperative jaw function, including maximum mouth opening and joint symptoms.

If there is a comparison group: Researchers will compare patients who received intraoperative PRP with those who received intraoperative PRF to assess differences in postoperative pain, functional outcomes, and joint-related symptoms.

Participants will:

Have their existing medical records reviewed retrospectively.

Provide postoperative outcome data derived from routine clinical follow-up, with no prospective recruitment or intervention.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

700

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Meikun Wang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult patients aged 18 to 75 years who underwent unilateral or bilateral temporomandibular joint arthroscopy at a single institution. All patients received intraoperative intra-articular injection of platelet-rich plasma (PRP) or platelet-rich fibrin (PRF) as part of routine clinical care. This is a retrospective observational study based on review of existing medical records, with no prospective recruitment or intervention.

Description

Inclusion Criteria:

Patients aged 18 to 75 years (inclusive)

Underwent unilateral or bilateral temporomandibular joint (TMJ) arthroscopy

Received intraoperative platelet-rich plasma (PRP) or platelet-rich fibrin (PRF) injection during TMJ arthroscopy

Exclusion Criteria:

Age younger than 18 years or older than 75 years

Did not undergo TMJ arthroscopy

Did not receive intraoperative PRP or PRF injection

Incomplete clinical or follow-up data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1 - Platelet-Rich Plasma injection therapy group
Patients who received Platelet-Rich Plasma injections during surgery.
Group 2 - Platelet-Rich Fibrin injection therapy group
Patients who are receiving Platelet-Rich Fibrin injections during surgery.
Group 3 - non injection therapy group
Patients who are not receiving Platelet-Rich Plasma nor Platelet-Rich Fibrin injections during surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain intensity
Time Frame: from baseline to 6 months post-surgery.
The primary endpoint of the study is the change in pain intensity from baseline to 6 months post-surgery.
from baseline to 6 months post-surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
maximum unassisted opening (MMO)
Time Frame: baseline and various follow-up times in 6 months.
collect data about maximum unassisted opening (MMO)
baseline and various follow-up times in 6 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jingping Wang, MD, Ph.D.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 15, 2026

Primary Completion (Estimated)

January 31, 2026

Study Completion (Estimated)

February 5, 2026

Study Registration Dates

First Submitted

January 14, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 23, 2026

Last Update Submitted That Met QC Criteria

January 21, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024P003298

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Temporomandibular Joint Disorders

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe